Shares of Allurion Technologies, Inc. (ALUR) tumbled nearly 11% on Wednesday morning after the company’s fourth-quarter (Q4) ...

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Seven months after suspending sales of its weight loss balloon in France due to safety concerns, Allurion’s products are back on sale in the country. In August 2024, the US company agreed to ...

These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...

These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...

Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...